
Blocking gene boosts T-cell attacks on chronic hepatitis B virus and tumors
A research team led by Professor Zhou Xuyu from the Institute of Microbiology of the Chinese Academy of Sciences (CAS), in collaboration with researchers from Beijing Ditan Hospital and Capital Medical University, has identified ANKRD11 as a key regulator that reduces the activity of CD8+ T cells during chronic hepatitis B virus (HBV) infection and cancer. The researchers found that ANKRD11 suppresses the AP-1 signaling pathway, which usually helps CD8+ T cells mount effective responses against infections and tumors.








